Dianthus Therapeutics
DNTH
72 hedge funds and large institutions have $288M invested in Dianthus Therapeutics in 2019 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 25 increasing their positions, 18 reducing their positions, and 6 closing their positions.
39% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 18
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
3% more funds holding
Funds holding: 70 → 72 (+2)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% less ownership
Funds ownership: 4.53% → 4.52% (-0%)
31% less capital invested
Capital invested by funds: $419M → $288M (-$131M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alkeon Capital Management
New York
|
+$1.19M |
| 2 |
Russell Investments Group
London,
United Kingdom
|
+$732K |
| 3 |
State Street
Boston,
Massachusetts
|
+$658K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$617K |
| 5 |
CC
Casdin Capital
New York
|
+$534K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$6.41M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.78M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$577K |
| 4 |
LCM
Laurion Capital Management
New York
|
-$562K |
| 5 |
AG
Artal Group
Luxembourg
|
-$347K |
DNTH Hedge Fund Activity: Q3 2019 in Review
72 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Dianthus Therapeutics (DNTH) for Q3 2019, worth a combined $288M — down 31% from $419M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new DNTH positions and 6 closed out — a net gain of 2 holders — while 25 added to existing stakes and 18 trimmed.
The largest buyer was Alkeon Capital Management, adding an estimated $1.19M. The largest seller was Eventide Asset Management, cutting an estimated $6.41M.
- 72 institutional investors held Dianthus Therapeutics (DNTH) as of Q3 2019, up from 70 in Q2 2019.
- Funds reported $288M of Dianthus Therapeutics stock for Q3 2019, down 31% quarter-over-quarter.
- 8 funds opened new Dianthus Therapeutics positions in Q3 2019 and 6 closed out, a net change of +2 holders.
- The largest Dianthus Therapeutics buyer in Q3 2019 was Alkeon Capital Management, an estimated $1.19M added.
- The largest Dianthus Therapeutics seller in Q3 2019 was Eventide Asset Management, an estimated $6.41M sold.
Based on aggregated 13F filings for Q3 2019.